| On the debate of original drug versus generic drug | Mesut ÇETİN, Feyza ARICIOĞLU | 211–213 |
| Reliability and factorial validity of the Turkish version of the 20-item Toronto alexithymia scale (TAS-20) | Kemal SAYAR, Serhat ÇITAK, Y. Medine GÜLEÇ, Jeffrey BORCKARDT, Samet KÖSE, Cüneyt EVREN, Hüseyin GÜLEÇ | 214–220 |
| The effects of the duration of formal education on adult brain: A voxel-based morphometry (diffeomorphic anatomical registration using exponentiated lie algebra) DARTEL Study | Erol OZAN, Ömer KİTİS, Ali Saffet GÖNÜL, Özlem Donat EKER, Orhan DEMİREL, Çağdaş EKER | 221–226 |
| Sigaranın şizofrenili hastalarda P50 dalgası üzerine etkileri | Tayfun TURAN, Nazan DOLU, Canan KILIÇ, Aslı BEŞİRLİ, Ertuğrul ESEL, Saliha ÖZSOY | 227–235 |
| Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study | Aysen ESEN-DANACI, Oryal TAŞKIN, Ömer AYDEMİR, Artuner DEVECİ, Fatma TANELİ | 236–240 |
| P50 sensory gating in children and adolescents with developmental stuttering | Süheyla ÜNAL, Rıfat KARLIDAĞ, Cemal ÖZCAN, Sibel ALTINAYAR, Özlem ÖZCAN | 241–246 |
| The management of developmental stuttering: Child psychiatrists' perspectives | İbrahim DURUKAN, Müzeyyen ÇİYİLTEPE, Ayhan CÖNGÖLOĞLU, Koray KARABEKİROĞLU, Tümer TÜRKBAY | 247–254 |
| The effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective study | Şengül CANGÜR, Ayşegül AYDIN, Asıl SARANDOL, Vahap Ozan KOTAN, Selçuk KIRLI, Cengiz AKKAYA | 255–262 |
| Antipsychotic selection, combination, and dosing patterns of a group of psychiatrists working at non-teaching hospitals | Oğuz KARAMUSTAFALIOĞLI, Bahadır BAKIM, Sinem GÖNENLİ, Yasemin CENGİZ, Başak ÖZÇELİK | 263–272 |
| Oral antipsikotik kullanımına eklenmiş depo antipsikotik tedavisinin şizofreni hastalarının tedaviye uyumları üzerine etkisi | Şengül CANGÜR, Salih Saygın EKER, Gülnihal DENİZ, Selçuk KIRLI, Aslı SARANDOL, Cengiz AKKAYA | 273–278 |
|